National Western Life Group Exploring Strategic Alternatives, Bausch Health Surges on U.S. District Court's Decision, Kura Oncology Initiated with a Buy
- May 17th, 2023
- 633 views
National Western Life Group, Inc. (Nasdaq: NWLI) has announced its intention to explore strategic alternatives with the aim of maximizing value for its stockholders. At this stage, no specific decision has been made regarding a sale, merger, or other strategic transaction. The timing and outcome of this review process are uncertain.
$NWLI is currently trading at $378.15, experiencing a substantial increase of $110.86 or 41.47%, following the announcement.
Bausch Health Companies Inc. (NYSE: BHC) said that the U.S. District Court of Delaware has upheld the final judgment regarding Xifaxan 550 mg (used to treat irritable bowel syndrome and diarrhea in adults), which prevents the FDA from approving Norwich Pharmaceuticals' Abbreviated New Drug Application until Oct. 2, 2029.
$BHC is currently trading at $7.66, showing a significant increase of $1.64 or 27.16%.
BTIG Research has initiated coverage on Kura Oncology, Inc. (Nasdaq: KURA) with a Buy rating and a price target of $31
As of now, $KURA is trading at $12.68, reflecting a marginal increase of $0.16 or 1.28%
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login